Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Optimer Looks To Partner C. Diff Candidate After Trial Success

This article was originally published in The Pink Sheet Daily

Executive Summary

OPT-80’s success in the clinic dramatically improves Optimer’s ability to partner the product for a healthy sum.

You may also be interested in...

Optimer Rides High After OPT-80 C. Diff Trial Success

Phase III data show antibiotic non-inferior to Vancocin; additional trial results due mid-2009 with an NDA filing by year’s end.

Forest Vows To Double Pipeline Potential

Firm restates commitment to aclidinium for COPD.

As Cubicin Threats Line Up, Cubist Spells Out A Strategy

Firm seeks new indications, late-stage assets.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts